Try our beta test site
109 studies found for:    Open Studies | CLL OR SLL | Phase 1
Show Display Options
Rank Status Study
1 Recruiting Study of ME-401 in Subjects With Relapsed/Refractory CLL/SLL or FL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Small Lymphocytic Lymphoma;   Follicular Lymphoma
Intervention: Drug: ME-401
2 Recruiting Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
Conditions: Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: dimethyl fumarate
3 Recruiting A Phase I Study of AC0010 in Patients With Relapsed or Refractory CLL/SLL, MCL(Mantle Cell Lymphoma), DLBCL and Other Non-Hodgkin B-Cell Lymphoma
Condition: B-cell Lymphoma
Intervention: Drug: AC0010MA
4 Recruiting Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Conditions: B-Cell Prolymphocytic Leukemia;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Drug: Lenalidomide;   Other: Pharmacological Study
5 Recruiting A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCL
Conditions: Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Mantle Cell Lymphoma
Interventions: Drug: TGR-1202;   Drug: Ibrutinib
6 Recruiting A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CLL
Conditions: Chronic Lymphocytic Leukemia (CLL);   Relapsed;   Refractory
Intervention: Biological: EGFRt/19-28z/4-1BBL CAR T cells
7 Recruiting Phase 1/2A Dose Escalation Study in CLL, SLL or NHL
Conditions: Follicular Lymphoma (FL/Indolent NHL);   Aggressive NHL (a NHL);   Chronic Lymphocytic Leukemia (CLL) / Small Lymphocytic Lymphoma (SLL);   T-cell Lymphoma (PTCL and CTCL);   B-cell Non Hodgkin Lymphoma (NHL)
Intervention: Drug: cerdulatinib (PRT062070)
8 Not yet recruiting Venetoclax and Ibrutinib in Patients With Relapsed/Refractory CLL or SLL
Conditions: Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma
Interventions: Drug: Ibrutinib;   Other: Laboratory Biomarker Analysis;   Other: Pharmacological Study;   Drug: Venetoclax
9 Recruiting Dose Escalation Study to Evaluate the Safety, Tolerability and Biological Activity of a Single Dose of UCART19 in Patients With Relapsed / Refractory (R/R) B-cell Acute Lymphoblastic Leukaemia (ALL) and Chronic Lymphocytic Leukaemia (CLL)
Conditions: Acute Lymphoblastic Leukaemia;   Chronic Lymphocytic Leukaemia
Intervention: Genetic: UCART19
10 Recruiting Phase I Dose Escalation Study of IMMU-114 in Relapsed or Refractory NHL and CLL
Conditions: Non-hodgkin's Lymphoma;   Follicular Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Chronic Lymphocytic Leukemia;   Small Lymphocytic Lymphoma
Intervention: Drug: IMMU-114
11 Recruiting ACY-1215 in Combination With BCR Pathway Inhibitors in Relapsed CLL
Condition: Recurrent Chronic Lymphoid Leukemia
Interventions: Drug: ACY-1215;   Drug: Ibrutinib;   Drug: Idelalisib
12 Recruiting A Study of Venetoclax in Combination With Bendamustine + Rituximab or Bendamustine + Obinutuzumab in Participants With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia (CLL)
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Bendamustine;   Drug: Obinutuzumab;   Drug: Rituximab;   Drug: Venetoclax
13 Recruiting UC-961 (Cirmtuzumab) in Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Intervention: Drug: cirmtuzumab
14 Recruiting A Study of Obinutuzumab(GA101) in Combination With High-Dose Methylprednisolone(HDMP) in Chronic Lymphocytic Leukemia(CLL) Patients (GA101 & HDMP)
Condition: CLL
Intervention: Drug: GA101/HDMP
15 Recruiting Phase 1b Safety and Efficacy Study of TRU-016 and Rituximab, Obinutuzumab, Idelalisib, or Ibrutinib in Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Biological: 20 mg/kg TRU-016 + Rituximab;   Biological: 10 mg/kg TRU-016 + Rituximab;   Biological: TRU-016 20 mg/kg + Obinutuzumab;   Biological: TRU-016 6-20 mg/kg + idelalisib + rituximab;   Biological: TRU-016 10-20 mg/kg + ibrutinib
16 Recruiting A Study Evaluating the Safety of Tocilizumab in Addition to Standard of Care Premedication Given Before Obinutuzumab + Chlorambucil in Participants With Untreated B-Cell Chronic Lymphocytic Leukemia (B-CLL) and Comorbidities
Condition: B-Cell Chronic Lymphocytic Leukemia
Interventions: Drug: Chlorambucil;   Drug: Obinutuzumab;   Drug: Placebo;   Other: Standard Premedication;   Drug: Tocilizumab
17 Recruiting Obinutuzumab With High-dose Ibrutinib for the Treatment of Patients With Chronic Lymphocytic Leukemia With Progressive Disease on Single Agent Ibrutinib.
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: ibrutinib;   Drug: obinutuzumab
18 Recruiting A Study of Ibrutinib + Obinutuzumab in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia
Condition: Chronic Lymphocytic Leukemia
Interventions: Drug: Obinutuzumab;   Drug: Ibrutinib
19 Recruiting Safety Study of BTK Inhibitor, DTRMWXHS-12, Used Singly or in Combination, in CLL and B-cell Lymphomas
Conditions: Chronic Lymphocytic Leukemia;   B-Cell Lymphoma
Interventions: Drug: DTRMWXHS-12;   Drug: DTRM-505;   Drug: DTRM-555
20 Not yet recruiting Entospletinib and Obinutuzumab in Treating Patients With Relapsed Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Non-Hodgkin Lymphoma
Conditions: Anemia;   B-Cell Prolymphocytic Leukemia;   Fatigue;   Fever;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3a Follicular Lymphoma;   Hairy Cell Leukemia;   Lymphadenopathy;   Lymphocytosis;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Marginal Zone Lymphoma;   Night Sweats;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Small Lymphocytic Lymphoma;   Richter Syndrome;   Splenomegaly;   Thrombocytopenia;   Weight Loss
Interventions: Drug: Entospletinib;   Other: Laboratory Biomarker Analysis;   Biological: Obinutuzumab;   Other: Pharmacological Study

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Study has passed its completion date and status has not been verified in more than two years.